Tate & Lyle continues to struggle

Following the profits warning issued in February, Tate & Lyle shares have continued to struggle.

The primary reason for the profits warning and the collapse in the share price has been an overhang of unsold sucralose, the primary component in Splenda. This is due to oversupply from Chinese manufacturers, and has resulted in a price fall of 15% this year. As sales of sucralose account for around a fifth of the company’s profits, Tate & Lyle has been forced to reduce its outlook for the year.

Subsequently, the company has embarked on a purchasing run of operations in China. The manufacturing facility produces polydextrose, which is one of the more successful soluble fibres that can be used for bulking up dietary foods. It also has a beneficial effect to the digestive systems.

Although recent acquisitions will have a longer-term benefit for the company, these are unlikely to materialise in the short term, and the share price is being more directly affected by the profits warning. Even though the shares, at 620p, are hovering around lows last seen in June 2012, a cautious outlook ahead of the release of annual figures would be prudent. 

Tate & Lyle chart

IGA, may distribute information/research produced by its respective foreign marketing partners within the IG Group of companies pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the research is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, IGA accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact IGA at 6390 5118 for matters arising from, or in connection with the information distributed.

This information/research prepared by IGA or IGA Group is intended for general circulation. It does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should take into account your specific investment objectives, financial situation or particular needs before making a commitment to trade, including seeking advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. In addition to the disclaimer above, the information does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. Any views and opinions expressed may be changed without an update.

See important Research Disclaimer.

Find articles by analysts